Cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus patients. There are no U.S. Food and Drug Administration approved therapies for CLE, and these lesions are frequently disfiguring and refractory to treatment. The present review will cover the recent inroads made into understanding the mechanisms behind CLE lesions and discuss promising therapeutic developments.
INTRODUCTION
Cutaneous lupus erythematosus (CLE) is a frequent finding in patients with systemic lupus erythematosus (SLE) and can also exist as a single entity without associated systemic autoimmunity. Despite ongoing research into the cause of CLE, it remains unclear how CLE relates to SLE pathogenesis. The present review will summarize the recent advances in the pathogenesis of CLE, its relation to SLE, and the evolving therapeutic approaches based on these findings.
WHAT IS CUTANEOUS LUPUS ERYTHEMATOSUS?
The frequency of cutaneous manifestations in SLE is as high as 70% [1] , and the overall prevalence of CLE is reported as greater than 0.07% [2] and may be equivalent to SLE in some populations [3 & ]. Subtypes of CLE are currently grouped on the basis of histology, lesion duration, clinical findings, and laboratory abnormalities [4, 5] and are summarized in Table 1 [6] [7] [8] [9] .
In 2013, the Third International Meeting on Cutaneous Lupus Erythematosus was held with a goal of developing a uniform definition for CLE, and consensus on diagnostic and classification criteria. A more formal process is currently underway, employing the Delphi consensus method with an initial goal of better characterizing discoid lupus erythematosus (DLE) [10] . One current diagnostic challenge is the definition of what constitutes SLE with cutaneous features versus CLE as an independent disease. Previous studies have suggested that SCLE has a higher incidence of systemic disease [7] , but most patients with SCLE who formally meet criteria for SLE do so based on mucocutaneous and laboratory criteria [11 && ]. Furthermore, neither the American College of Rheumatology (ACR) nor the Systemic Lupus International Collaborating Clinics (SLICC) criteria for diagnosis of SLE are able to sufficiently distinguish patients with SCLE and major internal disease from those without significant systemic manifestations [11 && ]. This proposes a challenge for epidemiologic and mechanistic studies that try to characterize CLE only from SLE-associated skin lesions and further work in this arena is warranted.
PATHOGENESIS
The pathogenesis of CLE is multifactorial and involves genetic predisposition, environmental triggers, and abnormalities in the innate and adaptive immune response. Current dogma points to UV irradiation as a mechanism for cellular damage and apoptosis in addition to dendritic cell activation, T-cell dysregulation, cytokine imbalances, B-cell defects, and autoantibody production ( Fig. 1 ). Recent advances are summarized next.
Genetics/epigenetics/transcriptomics
The list of genes involved in regulation of CLE disease risk is growing. Human leukocyte antigen (HLA) type may predict CLE variant risk [12, 13] . Tumor necrosis factor-a (TNFa) and complement promoter variants have also been linked with CLE [14] . Single nucleotide polymorphisms (SNPs) in tyrosine kinase 2 (TYK2), interferon (IFN) regulatory factor 5 (IRF5), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) may also increase risk for CLE. Recently, a large GWAS of 183 CLE cases and 1288 controls was completed and most genes reinforced the linkage of SNPs in various HLA genes. Novel associations for CLE risk in the GWAS included polymorphisms in casein kinase 2, a gene
KEY POINTS
Definitions of cutaneous lupus or cutaneous lupus associated with systemic lupus are being refined.
Many genetic risk factors for cutaneous lupus involve HLA or interferon-related pathways.
More work is needed to identify the pathogenic mechanisms behind cutaneous lupus manifestations.
Type I interferon receptor blockade may be a promising therapy for cutaneous lupus. ] identified 36 and 37 unique differentially methylated regions associated with malar rash and discoid rash, respectively. Hypomethylation of MIR886 and TRIM69 and hypermethylation of RNF39 were identified in patients with malar rash; these genes help mediate cell proliferation and apoptosis. Discoid rash-specific hypomethylated DMRs were found in TAP1 and PSMB8, genes involved in antigen processing and presentation.
New research has also identified transcriptional changes in CLE. When compared with psoriasis, DLE has a strong Th1 signature and an absence of IL-17 signaling [20]. Others have confirmed this finding and have identified progressive TGFb production in DLE, which may contribute to scar and fibrosis of lesions over time. Further, there is substantial overlap noted between dysregulated pathways of the skin of patients with DLE and the transcriptional profiles from the blood of DLE patients, most notably in type I IFN signaling [21 & ]. These data support a strong role for T cells in DLE and continue to support a role for type I IFN in CLE lesions.
Triggers of cutaneous lupus erythematosus lesions
UV exposure is a common trigger for CLE, with photosensitivity rates reported at 81% [22] . UV induces keratinocyte apoptosis, inflammatory cytokine production, and autoantigen exposure [23]. CLE lesions highly express Fas (CD95), which activates the extrinsic apoptotic pathway [24] . It is unclear whether UV drives enhanced apoptosis in lupus versus control skin as two studies [25, 26] addressing this question have disparate findings. However, recent studies have identified other mechanisms by which UV irradiation may influence skin disease. UV-induced apoptotic binding of the nucleolus by C1q may serve as a protective mechanism in SLE and further explain the role of C1q deficiency in SLE development [27] . Prediction of photosensitivity via global peptide profiling has identified b2 microglobulin as a potential predictor of photosensitive responses [28 & ]. Further work into the role of UV activation of CLE will likely identify additional targets for treatment.
The relationship of active skin disease to systemic disease activity is another area of exploration in CLE. UV irradiation is able to trigger activation of systemic lupus disease in male BXSB mice [29] . In line with these data, photosensitive patients with robust cutaneous infiltrates have more systemic symptoms, such as fatigue and arthralgias, than patients without skin inflammation after UV exposure [22] . Other murine models of skin inflammation also suggest a link with systemic disease. Epidermal injury via tape stripping can induce chronic rash and rapid induction of nephritis in lupus-prone NZM2328 mice [30 && ]. Furthermore, epicutaneous stimulation with TLR7 agonists also induces a lupus-like disease in wild type mice [31] . These data suggest that cutaneous inflammation promotes systemic disease activity and that identification of the specific mediators responsible will establish novel targets to prevent disease flare. Further research into this area is needed.
Cytokines/chemokines
Various cytokines and chemokines have been identified as contributing to CLE pathogenesis. TNFa is upregulated after UVB exposure at least partially through IL-1a signaling pathways [32] . Furthermore, TNFa induces surface expression of the autoantigen Ro52 in primary keratinocytes following TNFa stimulation [33] , which is interesting given known associations between Ro positivity and cutaneous lupus lesions. TNF-like weak inducer of apoptosis (TWEAK) stimulation of keratinocytes upregulates CCL5/RANTES, and skin disease in MRL/lpr mice is dependent on activation of the receptor for TWEAK [34 && ]. Chemerin, a chemokine for plasmacytoid dendritic cells, has been identified as upregulated in CLE and by UVB exposure and consequently may participate in recruitment of this cell population in CLE [35] .
Patients with CLE demonstrate increased expression of the IL-18 receptor on keratinocytes, and CLE keratinocytes fail to express IL-12, which is protective against apoptosis, in the presence of IL-18 [36] . Serum levels of IL-18 are higher in patients with anti-Ro antibodies [37] . Interestingly, polymorphisms in the IL-18 promoter have been identified in some lupus patients [38] .
Based on recent trial data, interest in type I IFNs as primary contributors to cutaneous lesions is strong. Increased expression of IFN-regulated genes is seen in both the dermis and epidermis of CLE lesions [39] . Type I IFN production in lupus lesions promotes a Th1-biased inflammatory infiltrate [39] . Type I IFNs also promote upregulation of PSMB9, an immunoproteasome subunit, in the epidermis of cutaneous lupus which may lead to enhanced extracellular matrix deposition in CLE [40 & ]. Interferonopathies, a recently identified class of genetic diseases which result in hyperactivation of type I IFN genes (reviewed in [41 & ]) have an abundance of CLE-like lesions, emphasizing the role of type I IFNs in this process.
Autoantibodies
Lupus is characterized by production of multiple autoantibodies. In CLE, autoantibodies frequently deposit at the dermal-epidermal junction and may facilitate antibody-dependent cell-mediated cytotoxicity. However, their specific role in the pathogenesis of cutaneous lupus remains unclear. Recent work has focused on identifying correlations between autoantibody production and CLE subtypes and clinical presentations. In a study by Biazar et al. [42] , anti-Ro/SSA antibodies were found in 47.4% of patients with ACLE, 72.1% of patients with SCLE, and 22% of patients with DLE. Anti-LA/SSB antibodies were detected in 27.5% of patients with ACLE, 36.2% of patients with SCLE, and 7% of patients with DLE.
Additional studies have looked at the utility of autoantibodies as prognostic indicators. One analysis in a primarily Caucasian population identified an association between anti-Smith (Sm) antibodies and discoid rash and photosensitivity; an association between anti-Ro/SSA antibodies and malar rash, oral ulcers, and presence of rheumatoid factor; and an association between anti-U1RNP antibodies and Raynaud's and malar rash [43 & ]. Another study performed in a primarily Chinese SLE population demonstrated that photosensivity and discoid rash are associated with anti-SSA and SSB antibodies, whereas malar rash, mucositis, serositis, and arthritis are associated with anti-Sm, antiribonuclear protein, and antiphospholipid antibodies. Anti-double-stranded DNA antibodies were associated only with renal involvement in this study [44] . The discordant findings may be secondary to differences in ethnic backgrounds, but additional studies are needed to better clarify the relationship between autoantibody presence and disease manifestations.
TREATMENT
The treatment of cutaneous lupus remains a challenge. This is partly because of varying and often unpredictable response to therapy among different subtypes of cutaneous lupus, and even among different patients within subtypes. In addition, there has been a paucity of studies dedicated to the treatment of cutaneous lupus, and no agent specifically for cutaneous lupus has been approved to date. The authors of a 2009 Cochrane Database review were only able to conclude that fluocinonide cream may be more effective than hydrocortisone cream in DLE, and that acitretin is likely equally effective compared with hydroxychloroquine, but carries with it more frequent and severe adverse effects [45] . A study published this year by Reich et al. [46] evaluated current practices in the management of cutaneous lupus and highlighted a significant amount of variability between countries and even among individual physicians. However, there have been several studies in recent years introducing novel and potentially effective treatment options.
Standard therapies
Prevention is a cornerstone in the management of CLE, as UV irradiation is known to induce lesions and trigger flares of disease [47] . Consistent protection with sunscreen and avoidance of sun and UV exposure have been associated with better clinical outcomes in SLE [48] and these precautions should be a part of any treatment plan.
Topical corticosteroids remain the established first-line treatment of localized CLE [45, 49] . Topical tacrolimus has additionally demonstrated efficacy in treatment of localized lesions [50] . Intralesional steroids can be beneficial for DLE [49] . For widespread and recalcitrant disease, however, corticosteroid use is clearly limited by side effects. Several immunosuppressive and immunomodulatory drugs have, therefore, been tried as steroid-sparing agents. Among these, antimalarials are the most established treatment approach. Currently, chloroquine and hydroxychloroquine are first-line systemic treatment, according to dermatological guidelines [49, 51] . Mycophenolate and methotrexate have been used as part of combination therapy for cutaneous disease partially responsive or unresponsive to antimalarial therapies, with varying effect [52] [53] [54] [55] . There are limited data available for the efficacy of azathioprine, with approximately 10 patients described in the literature [56, 57] .
Evolving therapeutic approaches
A restrospective analysis published this year by Klebes et al. [58 & ] evaluated 34 patients treated with Dapsone, either as monotherapy or combined with antimalarials. The study demonstrated that Dapsone with/without antimalarials was effective in over 50% of patients. Four patients discontinued the drug because of side effects, including drug eruptions, peripheral neuropathy, and hemolytic anemia. Overall, the study suggests that Dapsone may be a good second-line therapy in CLE.
Another recent study [59 & ] evaluated the efficacy of increased hydroxychloroquine dosing in patients with refractory CLE. Thirty-four patients with hydroxychloroquine blood levels less than or equal to 750 ng/ml were included in this open-label study. The daily dose of hydroxychloroquine was increased to reach blood concentrations of greater than 750 ng/ml. The primary endpoint in the study was defined as a 20% improvement in the CLE Disease Area and Severity Index score. Eighty-one percent of patients in the study reached the primary endpoint and hydroxychloroquine doses were able to be decreased without subsequent flare in 15 of 26 responders. The potential side effects of increased hydroxychloroquine dosing (e.g. retinal toxicity) need to be considered, but in patients able to reduce dose without subsequent flare, this approach may be effective and could avoid risks associated with more immunosuppressive therapies.
Addition of quinacrine to low-dose hydroxychloroquine has also been suggested for management of CLE [60] . This approach has been widely used in previous years and has been reported in a recent prospective, longitudinal study [61] to be effective when hydroxychloroquine monotherapy fails. Further studies are needed to evaluate risk associated with this additive approach.
Novel therapeutic targets
Type I IFNs (IFNa/IFNb) have been a focus in the development of new drugs for the treatment of systemic lupus with generally disappointing results. Sifalimumab, an anti-IFNa antibody, demonstrated modest improvements on skin disease activity [62 & ]. Another anti-IFNa antibody, rontazilumab, was ineffective in a phase II study [63] . More recently, anifrolumab, a monoclonal antibody targeting the type I IFN receptor, the common receptor for all type I IFNs, has been developed. The drug is currently being tested in patients with SLE with preliminarily positive results. A phase II randomized, doubleblinded, placebo-controlled trial demonstrated significant reduction in arthritis and improvement in cutaneous disease in 305 patients with moderate to severe lupus [64 & ], making this agent a potentially important treatment option for CLE. These studies suggest that other type I IFNs, in addition to IFNa, may have synergistic effects in CLE pathogenesis.
Tocilizumab, a humanized monoclonal anti-IL-6 antibody, has additionally been studied in the treatment of systemic lupus in recent years. There is limited evidence for the efficacy of tocilizumab in cutaneous disease, but a case report describing marked improvement in severe tumid lupus lesions suggests that the drug could be a promising treatment for CLE [65] . Belimumab, a monoclonal antibody targeting B lymphocyte stimulator, has not been studied in CLE, but case reports also support consideration of this for future use [66] .
CONCLUSION
CLE encompasses several cutaneous diseases with common and unique pathogenic factors. Further research will identify and refine the mechanisms that lead to disease and facilitate development of specific therapies which go beyond general immunosuppressive approaches, especially for recalcitrant disease.
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